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PCAS was 3.3%, the overall adverse event rate was 3.1% and
the 30-day mortality rate was 1.2%. A chi-square analysis of the
adverse event rates revealed no clear relationship between the
study group and proportion of adverse events among all 18
studies (¥2 = 14.6, p > 0.10). Multiple sensitivity analyses were
conducted; however, no relationship between the study group
and proportion of adverse events resulted (¥2 = 11.2, p > 0.10).
CONCLUSION: Although practitioners await stronger evi-
dence, this study demonstrates the relatively low rates of adverse
events in PCAS relative to CAS alone and the warranted use of
PCAS.
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OBJECTIVE: This study was conducted to assess the risk of
thromboembolic and bleeding events among atrial ﬁbrillation
patients treated with warfarin. METHODS: Using claims data
from a large commercial health plan, patients with chronic atrial
ﬁbrillation were identiﬁed based on medical claims with diag-
nosis codes 427.31 and 427.32 from 1998 through 1999.
Patients with valvular disease were excluded. Cox proportional
hazards analysis was used to compare risk of venous, arterial,
intracranial, and total thromboembolic events between warfarin
exposed and unexposed subjects. Risk of bleeding events was
also compared. RESULTS: A total of 6764 subjects were retained
for analysis; of these 3541 (52.4%) were exposed to warfarin
during the follow-up period. Among thromboembolic events,
treated subjects were signiﬁcantly less likely to experience arter-
ial events compared to non-treated subjects (HR: 0.710, CI:
0.540–0.934). No differences in the risk of venous or intracra-
nial events were found, nor in the risk of thromboembolic events
overall. Use of warfarin signiﬁcantly increased the risk of minor
bleeding events (HR: 3.600, CI: 2.537–5.109), and all bleeding
events (HR: 1.502, CI: 1.289–1.749). CONCLUSIONS: A large
number of atrial ﬁbrillation patients are not being treated with
warfarin. After adjusting for baseline characteristics, the risk of
thromboembolic events in this population was not signiﬁcantly
different between those exposed and unexposed to warfarin.
There was a signiﬁcant increase in the risk for minor and total
bleeding events among patients treated with warfarin. Both
observational studies and decision analytic models have indi-
cated that the outcomes of warfarin therapy is highly dependent
of how it is managed. The present study seems to indicate that
there is a signiﬁcant gap between the performance of warfarin
in reducing the risk of thromboembolic events as shown in
tightly controlled clinical trials or coagulation clinics versus what
is achievable in general practice.
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OBJECTIVES: Diabetic patients have a higher risk of coronary
artery disease. Percutaneous coronary intervention (PCI) with
stenting has become the standard of care to repair coronary
vessel blockage. However, stenting increases the risk of throm-
bus formation at the implantation site. Platelet glycoprotein
IIb/IIIa antagonist drugs reduce this risk. This study examines
whether abciximab and eptiﬁbatide are cost-effective as adjunct
therapies in diabetic patients undergoing PCI with stenting.
METHODS: Included were diabetic patients undergoing elective
or urgent PCI with stenting. Clinical outcome data was extracted
from the published EPISTENT and ESPRIT trials. Abciximab (N
= 335) and eptiﬁbatide (N = 419), with stenting, were compared
to a treatment group of stent-only patients. Short-term (one year)
and long-term (survival-Markov model) decision analytic models
(DATA 4.0) were constructed from a Canadian provincial health
system perspective. Results are reported in 2001 Canadian
dollars and presented on a per person basis. A 5% discount rate
was used. Probabilistic sensitivity analysis (SA) was done using
Crystal Ball. RESULTS: For abciximab + stent, incremental costs
were higher (+$81) but clinical outcomes were better (-18.5%
major adverse cardiac events [MACE] and -3% mortality) rela-
tive to the stent-only group. The incremental cost-effectiveness
ratio for abciximab was $438 per MACE avoided and $2700
per death avoided. Abciximab + stent patients had 0.22 more
adjusted life years (LYs) than the stent-only group so the incre-
mental ratio was $368 per adjusted LYs gained. When compared
to the stent-only group, eptiﬁbatide + stent was dominant in
terms of costs (Incremental = $166), MACE rate (Incremental =
7.1%) and mortality (Incremental = 2%) over the short-term.
There was a 0.22LY increase for eptiﬁbatide. SA indicated that
drug acquisition and procedure costs were the major cost drivers.
Results were robust. CONCLUSIONS: Eptiﬁbatide and abcix-
imab (+stenting) are considered cost-effective in the treatment of
diabetic patients undergoing PCI.
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OBJECTIVES: The economic consequences of heart failure (HF)
in post-myocardial infarction (MI) patients can be severe.
Recently there has been an increase in the availability of drugs
aimed at treating or delaying the onset of post-MI HF. The objec-
tive of this study was to estimate differences in costs, number of
hospitalizations and outpatient visits in post-MI patients with
and without HF. METHODS: Claims data for patients hospi-
talized with a principal diagnosis of MI between 1998 and 2000
were used. Patients with a diagnosis of HF or MI in the six-
months preceding the initial MI were excluded. Data on 13,682
patients for a period of 3-years following discharge for initial MI
was available. The follow-up period was divided into 18 two-
month intervals. Mean costs were analyzed using a two-part
model (logistic and generalized linear model (GLM)), and out-
patient visits and hospitalizations were analyzed using a GLM
model with log-link. Clustering of observations within patients
was adjusted for, and bootstrapping was used to obtain standard
errors. Age, gender, type of MI, insurance type, and comorbidi-
